Early experience of seven hepatocellular carcinoma cases treated with regorafenib

Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.

Detalles Bibliográficos
Autores principales: Uchikawa, Shinsuke, Kawaoka, Tomokazu, Aikata, Hiroshi, Kodama, Kenichiro, Inagaki, Yuki, Hatooka, Masahiro, Morio, Kei, Nakahara, Takashi, Murakami, Eisuke, Hiramatsu, Akira, Tsuge, Masataka, Imamura, Michio, Kawakami, Yoshiiku, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230610/
https://www.ncbi.nlm.nih.gov/pubmed/30455925
http://dx.doi.org/10.1002/ccr3.1791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230610/
https://www.ncbi.nlm.nih.gov/pubmed/30455925
http://dx.doi.org/10.1002/ccr3.1791

Ejemplares similares